1. Home
  2. GHRS vs IMOS Comparison

GHRS vs IMOS Comparison

Compare GHRS & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • IMOS
  • Stock Information
  • Founded
  • GHRS 2018
  • IMOS 1997
  • Country
  • GHRS Ireland
  • IMOS Taiwan
  • Employees
  • GHRS N/A
  • IMOS N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • IMOS Semiconductors
  • Sector
  • GHRS Health Care
  • IMOS Technology
  • Exchange
  • GHRS Nasdaq
  • IMOS Nasdaq
  • Market Cap
  • GHRS 774.1M
  • IMOS 713.4M
  • IPO Year
  • GHRS 2021
  • IMOS N/A
  • Fundamental
  • Price
  • GHRS $13.10
  • IMOS $19.92
  • Analyst Decision
  • GHRS Strong Buy
  • IMOS
  • Analyst Count
  • GHRS 8
  • IMOS 0
  • Target Price
  • GHRS $30.63
  • IMOS N/A
  • AVG Volume (30 Days)
  • GHRS 307.7K
  • IMOS 12.9K
  • Earning Date
  • GHRS 11-13-2025
  • IMOS 11-04-2025
  • Dividend Yield
  • GHRS N/A
  • IMOS 3.19%
  • EPS Growth
  • GHRS N/A
  • IMOS N/A
  • EPS
  • GHRS N/A
  • IMOS 0.01
  • Revenue
  • GHRS N/A
  • IMOS $777,452,000.00
  • Revenue This Year
  • GHRS N/A
  • IMOS $3.76
  • Revenue Next Year
  • GHRS N/A
  • IMOS $5.93
  • P/E Ratio
  • GHRS N/A
  • IMOS $118.39
  • Revenue Growth
  • GHRS N/A
  • IMOS 0.89
  • 52 Week Low
  • GHRS $6.00
  • IMOS $12.78
  • 52 Week High
  • GHRS $20.50
  • IMOS $23.45
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 45.98
  • IMOS 62.94
  • Support Level
  • GHRS $13.00
  • IMOS $18.69
  • Resistance Level
  • GHRS $14.96
  • IMOS $20.79
  • Average True Range (ATR)
  • GHRS 0.78
  • IMOS 0.35
  • MACD
  • GHRS -0.00
  • IMOS 0.05
  • Stochastic Oscillator
  • GHRS 28.46
  • IMOS 65.06

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

Share on Social Networks: